Biondvax pharmaceuticals ltd. (BVXV)
CashFlow / Yearly
Dec'17
Cash Flows from Operating Activities:
Net loss

-9,966

Adjustments to reconcile net loss to net cash used in operating activities:
Adjustments to profit and loss items:
Depreciation and amortization

127

Net financial expenses (income)

3,142

Increase in liability with respect to government grants

-2,971

Share-based compensation

150

Change in employee benefit liabilities, net

2

Total adjustments to profit and loss

6,392

Changes in asset and liability items:
Decrease (increase) in other receivables

-897

Increase (decrease) in trade payables

-1,597

Increase (decrease) in other payables

-8

Total changes in asset and liability

692

Cash paid and received during the year for:
Interest paid

21

Interest received

4

Total cash paid and received

17

Net cash used in operating activities

-2,899

Cash Flows from Investing Activities:
Increase in short-term deposits

2,193

Purchase of property and equipment

1,300

Proceeds from sale of marketable securities

1,173

Increase in other long term assets

116

Net cash used in investing activities

1,950

Cash Flows from Financing Activities:
Proceeds from issuance of shares and options, net of issuance costs

16,063

Proceeds from exercise of options to employees

5

Proceeds from exercise of options to public

1,768

Net cash provided by (used in) financing activities

17,836

Exchange differences on balances of cash and cash equivalents

-828

Increase (decrease) in cash and cash equivalents

16,059

Non-cash activities:
Exercise of options to public

818